It’s the latest step from pharmacy benefit managers to respond to relentless criticism from politicians and regulators over ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback